Ipsen Company profile
Founded in 1929, Ipsen (IPN) is a leading international biopharmaceutical group, focusing on specialty care. The company develops and produces innovative medicines in 3 major areas: rare diseases, neurosciences and oncology. Ipsen also runs a consumer healthcare business. In general, the company sells over 20 drugs in more than 115 countries worldwide. Ipsen's R&D is focused on its differentiated and innovative technological platforms in the leading biotechnological hubs, based in Cambridge, the US, Oxford, the UK, and Paris-Saclay, France. Headquartered in Paris, the company employs 5,100 specialists. Included to the CAC Mid 60 index, the Ipsen share price (IPN) is set and traded on the Euronext Paris exchange.Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)